Leukemia | Norton Healthcare

Indication: Leukemia

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS-HH-002.SA in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Shanghai Bensheng Pharmaceutical Co., Ltd.

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.